cyrilzakka/clinical-trials huggingface dataset:
Water and Land-based Exercise for Children With Post COVID-19 Condition

The latest data indicate that post COVID-19 condition is frequent in children and adolescents, with the most common symptoms being fatigue, shortness of breath, exercise intolerance and weakness. Evidence that COVID-19 can have significant long-term effects on children's health highlights the need for measures to reduce the impact of the pandemic on children, ensuring that they receive appropriate treatments. Those experiencing post COVID-19 condition require more tailored exercise-related advice and improved support to be able to resume activities important to their individual well-being. To the best of our knowledge, no studies have yet addressed the issue of exercise programs for children with post COVID-19 condition.

The aim of this study, therefore, is to evaluate the effectiveness of different interventions on pulmonary function, exercise capacity, fatigue and quality of life in children with post COVID-19 condition.

This will be a randomized controlled study with pre and post intervention assessment. Children will be recruited from primary schools and primary health care units in Warsaw. Participants meeting the inclusion criteria will be randomized to one of 3 groups: water-based exercise, land-based exercise or control (no exercise). The water-based and land-based exercise groups will be held twice a week, 45 min per session for 8 weeks. Participants will be assessed at baseline and immediately post-intervention in terms of changes in pulmonary function, exercise capacity, fatigue and quality of life. Research outcomes will build the evidence-based practice for health professionals.


Eligibility Criteria:
Inclusion Criteria:

* presenting symptoms of post-COVID-19 condition confirmed by the diagnosis by general practitioner (including obligatory fatigue and shortness of breath/respiratory problems)
* age 10-12 yrs old
* adapted to aquatic setting
* \<12 pts in the Ruffier test

Exclusion Criteria:

* contraindications to exercise
* chest pain
* physical activity trainings more than 2 times per week one month prior the study
Ultrasound Applications for Emergency Medical Technicians in Taiwan

The goal of this prospective observational study is to develop and assess the core ultrasound applications for emergency medical technicians (EMTs) in Taiwan. The study focuses on advanced emergency medical technicians (EMT-Ps) and their ability to perform point-of-care ultrasound (POCUS) in prehospital settings.

The main questions it aims to answer are:

Can a standardized POCUS training program improve EMT-Ps' competency in ultrasound applications? What is the reliability and validity of the newly established POCUS assessment modules for EMT-Ps? Researchers will compare trained EMT-Ps' ultrasound proficiency and clinical decision-making before and after training to see if structured POCUS education enhances diagnostic accuracy and patient care in prehospital settings.

Participants will:

Attend a structured POCUS training program, including lectures and hands-on practice with standardized patients and simulation models.

Undergo competency assessments, including written exams, objective structured clinical examinations (OSCEs), and image interpretation tests.

Perform ultrasound scans on actual patients in prehospital settings, focusing on trauma, respiratory distress, stroke, and cardiac arrest cases.

Receive feedback and participate in follow-up assessments to evaluate knowledge retention and clinical application.


Eligibility Criteria:
Inclusion Criteria:

* Patients presenting with one of the following conditions in the prehospital setting:

Trauma Dyspnea (shortness of breath) Suspected stroke Out-of-hospital cardiac arrest (OHCA)

Exclusion Criteria:

* Patients with hemodynamic instability or critical conditions requiring immediate resuscitation, making them unsuitable for focused prehospital ultrasound performed by EMT-Ps.
* Patients under the age of 18.
Fetal Cardiac Functions in Fasting Pregnant Women

In this study, we aimed to evaluate fetal cardiac functions after a fasting period of at least 10 days. The purpose of this study was to determine the unexpected effects of fasting on fetal cardiac functions.

Pregnancies at 24-34 weeks of gestation who present to our hospital for routine antenatal follow-up will be evaluated. As the study group, singleton uncomplicated pregnancies with at least 10 days of fasting will be assessed. All ultrasonographic examinations will be conducted within the last 2 hours of the fasting period. The control group will consist of healthy pregnant women who do not fast, with singleton uncomplicated pregnancies between 24-34 weeks, matched for age, parity, and gestational age.

Eligibility Criteria:
Inclusion Criteria:

* Singleton, uncomplicated pregnancies that have been fasting for at least the last 10 days
* Present for routine antenatal follow-up between 24-34 weeks of gestation

Exclusion Criteria:

* Multiple pregnancy
* Premature rupture of membranes
* Chorioamnionitis
* Placental abruption
* Severe fetal growth restriction
* Congenital fetal anomalies
* Preeclampsia
* Oligohydramnios
* Maternal diabetes -Conditions where fasting is contraindicated for the mother. -
Study on Post-acute Myocardial Infarction Ventricular Defect: Outcome Evalutation in Relation to Surgical Timing

The main objective of the study is to identify the optimal surgical timing for the treatment of intraventricular defects after acute myocardial infarction.

Identify the optimal timing for the treatment of post-infarction ventricular defect, considering the time interval between the clinical-instrumental diagnosis and the surgical intervention.

Eligibility Criteria:
Inclusion Criteria:

* Patients over eighteen years of age
* Patients with post-myocardial infarction ventricular septal defect treated surgically
* Patients who have signed the informed consent

Exclusion Criteria:

* Patients with post-infarction ventricular septal defect treated with medical/conservative therapy
* Patients with ventricular septal defects not due to acute myocardial infarction
Colloid Co-hydration and Vasoconstrictor Infusion for Prevention of Hypotension During Cesarean Section

This will be a double-blind randomized study, aiming at investigating a fixed rate phenylephrine infusion versus a fixed rate norepinephrine infusion versus placebo in combination with co-hydration with colloids for the prevention of maternal hypotension in elective cesarean section

Neuraxial techniques are the anesthetic techniques of choice in contemporary obstetric anesthesia practice, with a definitive superiority as compared to general anesthesia, since, by their use, serious complications involving the airway can be avoided.Spinal anesthesia has become the favorable technique for both elective and emergency cesarean section due to a quick and predictable onset of action, however, it can be frequently complicated by hypotension, with incidence exceeding 80% occasionally.

The aim of the current randomized controlled double-blinded trial was to compare the effect of a fixed-rate norepinephrine infusion versus a fixed-rate phenylephrine infusion versus placebo in parturients subjected to elective cesarean section under combined spinal-epidural anesthesia. All parturients will also receive colloid co-hydration.

Eligibility Criteria:
Inclusion Criteria:

* adult parturients, American Society of Anesthesiologists (ASA) I-II,
* singleton gestation\>37 weeks
* elective cesarean section

Exclusion Criteria:

* Body Mass Index (BMI) \>40 kg/m2
* Body weight \<50 kg
* Body weight\>100 kg
* height\<150 cm
* height\>180 cm
* multiple gestation
* fetal abnormality
* fetal distress
* active labor
* cardiac disease
* pregnancy-induced hypertension
* thrombocytopenia
* coagulation abnormalities
* use of antihypertensive medication during pregnancy
* communication or language barriers
* lack of informed consent
* contraindication for regional anesthesia
Terlipressin Infusion in Variceal Hemorrhage

Randomized, open label study of intravenous terlipressin infusion vs. bolus for the treatment of variceal hemorrhage. 24 hour regimen consisting of intravenous terlipressin will be used either at a rate of 0.5mg/hour or 2mg bolus every 4 hourly. Participants will be randomized into intervention and control arm using block randomization by computer generated random numbers. Efficacy will be assessed by clinical improvement in symptoms and signs of GI bleed. To assess safety, frequency and degree of adverse reactions will be observed. Periodic assessments until 5 days will be done consisting of physical examination, safety assessments, vital signs and lab tests.

Randomized, open label trial, conducted on patients admitted with acute variceal hemorrhage at The Aga Khan University Hospital, Karachi (AKUH). Patients will be followed in clinic after discharge to assess survival for 6 weeks.

Intravenous terlipressin will be obtained from Clinical Trials Unit, AKUH pharmacy in standard IV infusion form. Following complete clinical and laboratory evaluation, assessing the patient for eligibility, informed consent will be obtained from all the participants who are willing to be part of this study. After obtaining the informed consent, study participants will be randomized into the intervention arm (continuous infusion of Terlipressin) or the control arm (bolus form of Terlipressin). Participants who are randomized to the intervention arm will be administered a continuous infusion of Terlipressin at a rate of 0.5mg/hour for the first 24 hours. Participants randomized into the control group will be administered a bolus form of Terlipressin at a rate of 2mg every six hourly for the first 24 hours respectively. In case of weekends/public holidays intravenous terlipressin will be obtained from the main pharmacy of AKUH.

The trial will be conducted in in-patient units of AKUH where eligible patients are admitted. It may include emergency room, special care unit and general ward. Moreover, patients will be followed up by phone calls and in outpatient's clinics to assess survival six weeks post discharge.

Eligibility Criteria:
Inclusion Criteria:

1. Age between 18 to 60 years
2. Either gender
3. A diagnosis of liver cirrhosis;
4. Initial presentation with acute gastroesophageal variceal bleeding
5. Willing to provide informed consent to participate in the study (by study subject or next of kin)

Exclusion Criteria:

1. Age \< 18 or \> 60 years
2. Not willing to provide consent due to any reason
3. No liver cirrhosis
4. Acute upper gastrointestinal bleeding unrelated to varices;
5. Use of somatostatin or octreotide.
6. Hepatocellular Carcinoma (HCC)outside Milan's criteria
7. Advance cardiovascular, pulmonary or renal disease (e.g. asthma, hypertension, arrhythmia, renal insufficiency)
8. History of hypersensitivity to Terlipressin
9. Pregnancy
10. Patients already admitted at AKUH who develop upper GI bleed during admission.
Cliavist in Infectious and Degenerative Diseases of the Spine

USPIO contrast enhancement results from intracellular trapping of the iron particles in reactive cells, especially macrophages. 17FDG-PET studies have demonstrated that macrophages are present in spine infectious diseases but are absent in spine degenerative diseases. The aim of this work is to compare the enhancement induced by CLIAVIST in both diseases. The absence of macrophages in degenerative lesions should help to differentiate them from infectious lesions, who should present contrast enhancement in relation to the presence of macrophages.


Eligibility Criteria:
Inclusion Criteria:

* spine infection or spine degenerative disease
* patient agreement obtained

Exclusion Criteria:

* pregnancy
* MRI contra-indications
* cliavist contra-indication
* dextran allergy
The Influencing Factors of Vancomycin Trough Level and the Rate Achieving the Target Trough Level

The aim of this study was to assess factors that may influence vancomycin trough level and the rate achieving the target trough level in critically ill patients.

This retrospective observational study included adult patients treated with intravenous vancomycin in intensive care unit of Zhongda Hospital from January 2015 to December 2017. Vancomycin dose was based on international consensus and adjusted according to estimated glomerular filtration rate (eGFR) calculated by the Cockcroft-Gault equation. vancomycin trough level (VTL) was retained at steady state (after the third dose). Linear regression was performed to determine the correlation between factors prior to the first vancomycin dose and VTL. Distribution of VTL and percentage of patients achieving the target trough level (15-20mg/L) was observed in different renal function.

Eligibility Criteria:
Inclusion Criteria:

* Adult ICU patients (age≥18 years) treated with intravenous vancomycin were included

Exclusion Criteria:

* Chronic renal dysfunction and acute renal injury patients treated with Renal Replacement therapy
* VTL was not retained at steady-state
* Vancomycin treatment time≤48h
* Vancomycin dose did not meet study definitions
* Palliative care
Topical Antibiotics in Chronic Rhinosinusitis

Researchers are trying to find out if patients develop antibiotic resistant organisms after the use of topical antibiotics in the treatment of chronic rhinosinusitis.

There is a certain group of patients that has chronic rhinosinusitis that has continued even with treatment including saline and steroid nasal irrigations as well as oral steroids and antibiotics and surgery.

In these patients, the use of topical antibiotic nasal rinses may be of benefit to their disease. The use of topical antibiotic nasal rinses is commonly used as standard of care already throughout the country for refractory chronic rhinosinusitis including here at the Mayo Clinic. Our pharmacy has compounded this medication for this specific purpose. As such, this study is not aimed at a 'novel medication', but rather to investigate the efficacy of a medication already in common use but without great evidence.

The investigators are doing this research study to find out if patients develop antibiotic resistant organisms after the use of topical antibiotics in the treatment of chronic rhinosinusitis.

In addition, this study will look at the effects of topical antibiotics on patient symptoms as measured by a patient survey called the Sino-Nasal Outcomes Test (SNOT-22) and in-office an exam of the inside of their nose, including with a scope (a camera on the end of a long tube).

Eligibility Criteria:
Inclusion Criteria:

* Male or female, between 18-80 years old, diagnosed with chronic rhinosinusitis who have undergone previous functional endoscopic sinus surgery including at minimum maxillary antrostomy and anterior ethmoidectomy
* Active mucopurulence on endoscopic examination with corresponding culture demonstrating pathogenic bacterial growth
* Completion of written informed consent
* No prior enrollment into this study
* Refractory to maximal medical therapy

Exclusion Criteria:

* Patient has not had prior endoscopic sinus surgery consisting of at minimum maxillary antrostomy and anterior ethmoidectomy
* Patient is currently being treated with oral antibiotics
* Patient has been treated with oral or topical antibiotics within the past 14 days
* Participation in an investigational drug study simultaneously with participation in this study
* Concurrent use of oral steroids
* Allergy to Tobramycin, Mupirocin, Gentamicin and Levofloxacin
* Known to currently be pregnant
Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis

This was a multi-center, randomized, double-blind, parallel group study. Efficacy Objectives: To evaluate the efficacy of CD2027 ointment 3 mcg/g applied twice daily over 4 weeks versus its vehicle in adult participants with at least moderate atopic dermatitis.

Safety objective: To evaluate safety of CD2027 ointment 3 mcg/g when applied twice daily over 4 weeks versus its vehicle on 5 percent (%) - 20% involved Body Surface Area (BSA) (excluding Head/Neck) in adult participants with at least moderate atopic dermatitis.


Eligibility Criteria:
Inclusion Criteria:

* Male or female participant, 18 years of age or older
* Clinical diagnosis of atopic dermatitis according to Hanifin and Rajka criteria, of at least moderate intensity according to Investigator Global Assessment (IGA greater or equal to 3)
* Body surface affected by the disease between 5% and 20% of total BSA, based on Rule of Nine's, excluding Head/Neck
* At least one area (Target Lesion) which was representative of the participant's disease state, was not located on the hands, feet or genitalia, measures at least 10 cm\^2, presented a Total Severity Score of at least 6/15 (total severity score defined as the sum of Erythema, Excoriation, Papulation/Induration, Oozing/Crusting and Lichenification) with oozing/crusting severity at most 1

Exclusion Criteria:

* The participant had albumin-adjusted calcium above the upper normal range from screening evaluation
* The participant had history/signs/symptoms suggestive of an abnormality of calcium homeostasis (such as hyperparathyroidism, Paget's disease, adrenal insufficiency, hyperthyroidism)
* The participant had signs/symptoms of urinary stones or has a history of urinary stones within the past 5 years prior to the Screening Visit
A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia

This randomized, double-blind, placebo- and active-controlled, parallel group study will evaluate the safety and efficacy of RO4917838 (bitopertin) in patients with acute exacerbation of schizophrenia. Patients will be randomized to receive either RO4917838 10 mg or RO4917838 30 mg or olanzapine 15 mg or placebo orally daily for 4 weeks as inpatients, with a 4-week follow-up period.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients, 18-65 years of age
* Diagnosis of schizophrenia (Diagnostic and Statistical Manual of Mental Disorders DSM IV-TR)
* Acute exacerbation which began within the prior 8 weeks
* Female patients must be surgically sterile or post-menopausal, or agree to use effective contraception for the duration of the study

Exclusion Criteria:

* Current psychiatric diagnosis other than schizophrenia
* Alcohol or substance dependence within 3 months or abuse within 1 month (except for nicotine)
* Electro-convulsive therapy (ECT) within the prior 6 months
* Previous treatment with RO4917838 or another GLYT inhibitor
* Current treatment with olanzapine, or previous treatment with intolerability or lack of response
* Treatment with long-acting injectable antipsychotic within 2 dosing intervals
* Treatment with \> 2 antipsychotics within 3 months
* History of neuroleptic malignant syndrome
* Have treatment-resistant schizophrenia as judged by treating physician or have failed two trials according to criteria in protocol
Study of CM310 in Healthy Subjects

This is a single center, randomized, double-blind, placebo-controlled, dose escalation study.


Eligibility Criteria:
Inclusion Criteria:

* Healthy male volunteers.
* aged ≥ 18 and ≤ 65 years old.
* With all clinical laboratory examination normal.
* Voluntary signing of the informed consent form.

Exclusion Criteria:

* With a history of asthma and allergic reactions.
* With a history of conjunctivitis and keratitis, as well as previous medical conditions.
* With positive results from alcohol breath or urine drug abuse testing.
Perioperative Database of Chinese Elderly Patients for Postoperative Acute Kidney Injury

To develop and externally validate a risk prediction model for postoperative acute kidney injury (PO-AKI) in elderly patients undergoing major noncardiac surgery, addressing the current gap in predictive tools for this vulnerable population.

The endpoint was the occurrence of PO-AKI within seven days following surgery. Diagnoses were based on the Kidney Disease: Improving Global Outcomes (KDIGO) criterion. Potential PO-AKI-related perioperative data were retrieved and extracted from electronic medical record for model derivation and validation.

Clinicians may consider implementing this externally validated risk prediction model to stratify elderly patients' PO-AKI risks in the early postoperative phases of noncardiac surgery in elderly patients.


Eligibility Criteria:
Inclusion Criteria:

* elderly patients (aged ≥ 65 years) undergoing non-cardiac surgeries

Exclusion Criteria:

* (1) Patients who underwent endoscopic or transplant procedures;
* (2) Patients who underwent surgeries lasting longer than 10 hours;
* (3) Patients who had severe preoperative kidney dysfunction, defined as preoperative sCr levels ≥ 353.6 μmol/L, or a baseline estimated Glomerular Filtration Rate (eGFR) \< 15 ml/min per 1.73 m2;
* (4) Patients without sCr values at baseline or during follow-up to detect PO-AKI occurrences.
Raltitrexed Concurrent With Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus

Concurrent chemoradiotherapy is one of the curative options for esophageal squamous cell carcinoma. We evaluated the efficacy and toxicity of raltitrexed with concurrent radiotherapy in elderly patients with esophageal cancer.


Eligibility Criteria:
Inclusion Criteria:

Histological or cytologic diagnosis of esophageal carcinoma. ECOG performance status 0-1. Age:70-85 years. Joined the study voluntarily and signed informed consent form Patients must not have received any prior anticancer therapy.

Stage IIa-Ⅳa(AJCC 2002). Target lesions can be measured according to RECIST criteria. No serious system dysfunction and immuno-deficiency, Adequate organ function including the following: Hemoglobin ≥9 g/dL, WBC≥3x109/L, Neutrophils (ANC )≥1.5x109/L, platelet count ≥100x 109/L, TBIL\<1.5 x ULN, ALT and AST ≦ 2.5 x ULN, creatinine ≦ 1.5 x ULN.

Exclusion Criteria:

Multiple carcinomas of the esophagus. Biopsy-proven invasion of the tracheobronchial tree or tracheoesophageal fistula.

Metastatic disease (M1b). A primary tumor that extended to within 2 cm of the gastroesophageal junction. Prior chemotherapy, prior thoracic radiation, surgical resection of the primary tumor.

history of a second malignancy other than nonmelanoma skin cancer.